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Simple Summary: This retrospective study reports on 10 patients with radiation-associated angiosar-
coma of the breast and chest wall treated during the past decade. In this rare disease local control
is highly dependent on the extent of surgery. Further treatment options are urgently needed. Re-
iradiation in combination with localized hyperthermia should be considered for adjuvant and defini-
tive treatment of nonresectable radiation-associated angiosarcomas. The presented hypofractionated
re-irradiation schedule with 5 × 4 Gy once per week immediately following wIRA-hyperthermia is a
promising option to further reduce the radiation dose recommended so far. This could reduce side
effects without compromising local control.
Abstract: Background: Radiation-associated angiosarcoma of the breast (RAASB) is a rare, challeng-
ing disease, with surgery being the accepted basic therapeutic approach. In contrast, the role of
adjuvant and systemic therapies is a subject of some controversy. Local recurrence rates reported in
the literature are mostly heterogeneous and are highly dependent on the extent of surgery. In cases
of locally recurrent or unresectable RAASB, prognosis is very poor. Methods: We retrospectively
report on 10 consecutive RAASB patients, most of them presenting with locally recurrent or unre-
sectable RAASB, which were treated with thermography-controlled water-filtered infrared-A (wIRA)
superficial hyperthermia (HT) immediately followed by re-irradiation (re-RT). Patients with RAASB
were graded based on their tumor extent before onset of radiotherapy (RT). Results: We recorded
a local control (LC) rate dependent on tumor extent ranging from a high LC rate of 100% (two of
two patients) in the adjuvant setting with an R0 or R2 resection to a limited LC rate of 33% (one
of three patients) in patients with inoperable, macroscopic tumor lesions. Conclusion: Combined
HT and re-RT should be considered as an option (a) for adjuvant treatment of RAASB, especially in
cases with positive resection margins and after surgery of local recurrence (LR), and (b) for definitive
treatment of unresectable RAASB.
Keywords: radiation-associated angiosarcoma of the breast; secondary angiosarcoma; re-irradiation;
wIRA-hyperthermia; superficial hyperthermia
1. Introduction
Radiation-associated (secondary) angiosarcoma of the breast (RAASB) is a highly ag-
gressive tumor that develops in previously irradiated areas. It occurs due to the utilization
of adjuvant radiotherapy (RT) mostly applied in the setting of breast-conserving treatment
in breast cancer. c-Myc amplification in RAASB is characteristic and differentiates RAASB
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from primary angiosarcoma of the breast [1,2]. Awareness of RAASB as a late side effect
of RT for breast cancer is essential to facilitate an early diagnosis. However, reddish-livid,
flat skin alterations may attract the attention of patients or physicians rather late, and
diagnosis is unfortunately often delayed. Since RAASB can easily be confounded with a
local hematoma, a skin biopsy should be performed for any suspicious lesion arising on a
previously irradiated breast [3].
Recently, several population-based studies [4–6], systematic literature reviews and
meta-analyses [7–9], as well as retrospective single-institution studies [2,10,11] have been
published. Epidemiological data from these publications are quite consistent and can be
summarized as follows: RAASBs develop in 0.1% of all breast cancer patients treated with
adjuvant RT in primary breast cancer care, occurring—on average—8 years after RT, at a
mean patient age of around 70 years. The incidence of RAASB is increasing, most likely due
to routinely performed adjuvant RT after breast-conserving surgery and due to prolonged
survival of breast cancer patients [12].
In contrast to data on incidence, prognostic data from recent publications are extremely
heterogeneous and differ considerably from data published several years ago. Five-year
overall survival (OS) in population-based surveys ranges from 22.5% in the SEER database
analysis of the National Cancer Institute (NCI) in the USA [13], 41% in the Netherlands [4],
50.5% in Italy [6], and 69% in Finland [5]. Including single-institution and systematic
literature reviews, the local recurrence rate (LRR) ranges from 35% [10], and 59% [7], to
66% [14]. Median recurrence-free survival (RFS) ranges from 4 months [15], 10 months [16],
23 months [4] up to 36 months [10]. Amongst others, this heterogeneity might be due to
low patient numbers including a large variation of tumor stages and prognostic factors,
missing treatment guidelines, and selection bias of case reports.
So far, there are no uniform treatment recommendations for RAASB. Surgery is ac-
cepted as the basic approach [5,17], wherein the extent of surgery is of major importance.
Nevertheless, the risk of local recurrence is high [14]. The role of adjuvant therapies and
the treatment strategy for recurrent and unresectable RAASBs remain unclear [18,19]. Due
to its radiation-induced etiology, there is a general reluctance of applying re-RT. To ad-
dress this challenge, modified fractionation schedules such as hyperfractionation [20] or
hypofractionation are used, with the latter combined with concurrent hyperthermia (HT)
as a radiosensitizer [21,22]. Radiosensitizing effects of HT include (a) an improved oxy-
genation as a consequence of increased blood flow at times of re-RT [23,24], (b) depletion of
glutathione levels [25], and (c) inhibition of DNA repair [26]. In addition, there is evidence
that mild HT (39 ◦C–43 ◦C) can activate anti-tumor immune responses (e.g., [27]). The
radiosensitizing effects allow for a significant reduction of the total re-RT dose [28]. Com-
bined thermography-controlled, water-filtered infrared-A (wIRA), contactless, superficial
HT with hypofractionated re-RT reveals excellent clinical effects in pre-irradiated locally
recurrent breast cancer (LRBC) providing high patient comfort and low toxicity [29]. This
hyperthermia technique guarantees large treatment fields, tissue temperatures >40 ◦C
up to 15 mm, and only low toxicity (mostly grade 1) due to permanent temperature
measurements all over the body surface avoiding any burns [30]. In the present retrospec-
tive analysis, we report the results of a cohort of RAASB patients treated with the same
treatment schedule of combined wIRA-hyperthermia and hypofractionated re-irradiation
(HT/re-RT). We discuss the results in relation to other previously published treatment
schedules and their outcomes.
2. Patients and Methods
Nine consecutive patients presenting with RAASB from 08/2011–06/2015 at the
Hôpital Cantonal, La Chaux-de-Fonds (Switzerland) and from 06/2015 to 12/2020 at
the Lindenhofspital, Bern (Switzerland), and one patient from 01/2019 to 12/2020 at the
University Medical Center, University of Freiburg (Germany), have been retrospectively
analyzed. Ethics votes were not required for retrospective analyses since patients have
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been treated in standard routine use. All patients gave informed consent to use their
anonymized data for scientific evaluation and publication.
Patients had previously been treated with adjuvant RT after breast conserving surgery
and adjuvant hormonal treatment. One patient had additionally received adjuvant chemother-
apy. The initial stage of breast cancer had been favorable, with lymph node involvement
in only one patient. Nine out of 10 patients had been treated using conventional RT-
fractionation with tangential fields comprising photons (6–15 MV linear accelerator), and
one patient had been treated with 60Co. Nine patients had received a tumor bed boost,
with seven of them using 9–12 MeV electrons (Table 1).





















Age at Dx 68 59 73 75 59 62 71 73 69 72
BC-Stage T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T2N0M0 T2N2aM0 T1N0M0 T2N0M0 T1N0M0
Grade G2 G2 G1 G2 G2 G2 G2 G2 G2 G3
BC-Tx BCS + RT +H
BCS + RT +
H
BCS + RT +
H
BCS + RT +
H
BCS + RT +
H
BCS + RT +
H
BCS + RT +
CT + H
BCS + RT +
H
BCS + RT +
H
BCS + RT +
H
RT Breast
(Gy) 25 × 2 28 × 1.8 * 25 × 2 25 × 2
21 × 1.8 **
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Dx = diagnosis, BC = breast cancer, BC-Tx = breast cancer treatment, BCS = breast conserving surgery, RT = radiotherapy, CT = chemotherapy,
H = hormonal therapy, * = postoperative RT delayed due to severe local infection of the reconstructed breast after surgery, ** = RT was
interrupted for 5 weeks due to local infection of the breast, afterwards 2nd course of whole breast RT and additional boost, 6 resp.
15 MV = RT with linear accelerator, 60Co = RT with Cobalt-60 machine, Ø = no boost, e− = electrons, MeV = energy of electrons.
Median latency period of RAASB was 6 years (range: 4.5–14) (Table 2). Clinical
observations such as skin type, hair color, the presence of benign and RT-related skin
alterations were also recorded. Five out of 10 patients presented with ruby points (cherry
hemangiomas), and 2 patients with fibrosis (thickening of the skin) (Table 2).
Tumor extensions at time of presentation at the RT department were divided into
4 categories: I = postoperative after R0, II = postoperative after incomplete resection
(inappropriate resection margin, R1, or R2 respectively), III = macroscopic lesions, limited
to the ipsilateral chest wall, not surpassing midsternal line, midaxillary line, clavicle or
lower costal margin, and IV = macroscopic lesion with far-reaching extension, reaching
the contralateral chest wall, supraclavicular fossa, abdominal wall or the back. In addition,
depth of infiltration as a putative prognostic factor was classified as follows: a = infiltration
limited to cutis and subcutis, and b = deep infiltration into the muscle layer (Figure 1).
None of the patients presented with distant metastases from RAASB.
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Clinical presentation and RT related skin alterations seen after surgery (mastectomy, further resections etc.) in the remaining previously
irradiated skin. BC-Tx = breast cancer treatment, Dx = diagnosis.
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Figure 1. Different RAASB categories as used in this retrospective study. I = postoperative after R0, II = postoperative
after incomplete resection (inappropriate margin, R1, or R2 respectively), III = macroscopic lesion limited to ipsilateral
chest wall, not surpassing midsternal and midaxillary line, clavicle and lower costal margin, IV = macroscopic lesion with
far-reaching extension, more than ipsilateral chest wall and supraclavicular fossa and/or contralateral chest wall or breast
and/or abdominal wall and/or extension on the back. Lower right panel: Additional information on infiltration depth:
a = infiltration limited to skin/subcutis, b = deep infiltration into muscle layers.
2.1. Patient Groups
According to their different histories, patients were divided into 4 groups A–D (Table 3):
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Chemotherapy Ø Ø 2× Ø Ø Ø * 7× Ø Ø
Tumor
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HT/re-RT
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5 × 4 Gy
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5 × 4 Gy
1×/w
5 × 4 Gy
1×/w
5 × 4 Gy
1×/w
5 × 4 Gy
1×/w
5 × 4 Gy
1×/w
5 × 4 Gy
1×/w
5 × 4 Gy
1×/w + 2
× 4 Gy
5 × 4 Gy
1×/w
25 × 2 Gy
+ 5 × 2 Gy
Response
1st course - - - - - CR CR PD PR CR
Repeated










- - 6 3 - - - 0 (PD) 1 -
Survival
(mts) 67 37 20 45 10 16 1 1 7 18











Group A: Directly treated with adjuvant HT/re-RT after 1st surgery of a newly diagnosed RAASB. Group B: Patients treated with adjuvant
HT/re-RT after recurrence of RAASB initially treated with surgery alone. Group C: Patients treated with HT/re-RT after recurrences
developing within 3–4 weeks after 1st resection despite R0 resection. Group D: Patients with non-resectable recurrences after one or several
surgical treatments, treated directly with HT/re-RT. TM = total mastectomy, Mast. = modified mastectomy, Ø = not received, R status
1st Surg. = radicality after 1st surgical intervention, R status 2nd Surg. = radicality after 2nd surgical intervention, inop = inoperable
recurrence, CT = chemotherapy, Tumor extension: classification at the presentation in radiation oncology department: I = postoperative
after R0, II = postoperative after incomplete resection, III = macroscopic lesion limited to the ipsilateral chest wall, IV = macroscopic disease
far-reaching extension, suffix a = non deep infiltration, suffix b = deep infiltration, re-RT = re-irradiation, HT = hyperthermia, Tx = treatment,
LFU = Lost to follow up,* = patient presents distant metastasis of breast cancer under systemic treatment, together with palliative radiation
of different manifestations, therefore no further extensive surgery.
Group A: 2 patients (No. 1 and 2) presented directly after surgery of the RAASB, No. 1
with R2, No. 2 with R0 resection status.
Group B: 3 patients (No. 3, 4, and 5) presented after surgery of a recurrent RAASB,
No. 3 and 4 with R1, No. 5 with R0 resection status.
Group C: 2 patients (No. 6 and 7) presented with aggressive tumors developing a local
RAASB recurrence within 3–4 weeks after primary radical surgery despite R0 resection
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with preoperative biopsy mapping. In both patients the option of another extensive surgery
was abandoned due to the almost immediate recurrence with rapid extension over the
chest wall.
Group D: 3 patients (No. 8, 9, and 10) presented with large-sized unresectable recur-
rences of RAASB, patients No. 8 and 9 in a highly palliative situation. Patient No. 8 had
been heavily pretreated (e.g., 2 resections, 7 chemotherapies) and presented after the 3rd
RAASB recurrence with a tumor infiltrating into the muscle layer, and No. 9 presented with
a large tumor extending to the back. Patient No. 10 presented in a good general condition.
2.2. Treatment
Treatment planning was based on CT scan, former radiological investigations, e.g.,
MRI and PET-CT and clinical descriptions to define properly lateral tumor spread and
deep infiltration. RT- and HT-volumes were prescribed with margins of 5 to 10 cm around
all visible lesions whenever possible. That means that RT-fields, mostly using electrons,
were quite large and mainly limited by the machines’ capability. Electrons were chosen
because RAASB is considered a skin disease occurring in cutaneous/subcutaneous layers.
The treatment protocol consisted of weekly water filtered infrared-A (wIRA) superficial
HT for 45–60 min (hydrosun®TWH1500, Hydrosun Medizintechnik, Müllheim, Germany,
see Figure 2D), immediately followed by re-RT. The contactless energy deposition allows
for continuous thermography as well as visual control of the entire treatment field, which
is of crucial importance for critical skin conditions, e.g., skin transplants and mesh grafts
(Figure 2C,F). In addition, this technique produces very large treatment fields [30], mostly
even larger than radiation fields in order to cover completely the defined treatment volume.
The computer-based, closed feedback system of this device was set at a maximum skin
surface temperature of 43.0 ◦C (Figure 2E). This results in tissue temperatures >40 ◦C at
a tissue depth up to approximately 15 mm, and >39 ◦C up to a depth of 25–30 mm [30].
Patients No. 1–9 were treated with 4 Gy once per week for a total dose of 20 Gy, as
described in detail later [28–30]. Eight patients were irradiated with 6–9 MeV electrons
and a preheated bolus. Patient No. 8 had a combined photon–electron plan to cover
deep infiltration. Patient No. 10 received a conventionally fractionated re-RT with 50 Gy
(25 fractions with 2 Gy/fraction with photons) with an electron boost up to 60 Gy which
was combined with 6 weekly hyperthermia sessions, applied immediately before RT.









Figure 2. Documentation of patient No. 3. (A): Re-analysis of former radiotherapy 5 years prior to 
RAASB diagnosis: Field documentation of electron boost after tangential Cobalt-60 with 50 Gy 
(August 2006). (B): Initial RAASB, preoperative situation (May 2011). Note, that RAASB occurred 
outside former electron boost. (C): Third local recurrence within the grafted skin (arrows, May 
2014). (D): During treatment with hydrosun®TWH 1500. (E): Corresponding thermography images 
during wIRA-hyperthermia: critical regions such as skin transplantation can be controlled visually 
and protected efficiently without causing burns. (F) Follow up 2.5 months after re-RT with 5 × 4 
Gy + wIRA-hyperthermia 1×/week (September 2014). 
Figure 2. Cont.
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Figure 2. Documentati n of patient No. 3. (A): Re-analysis of former radiotherapy 5 years prior
to RAASB diagnosis: Field documentation of electron boost after tangential Cobalt-60 with 50 Gy
(August 2006). (B): Initial RAASB, preoperative situation (May 2011). Note, that RAASB occurred
outside former electron boost. (C): Third local recurrence within the grafted skin (arrows, May 2014).
(D): During treatment with hydrosun®TWH 1500. (E): Corresponding thermography images during
wIRA-hyperthermia: critical regions such as skin transplantation can be controlled visually and
protected efficiently without causing burns. (F) Follow up 2.5 months after re-RT with 5 × 4 Gy +
wIRA-hyperthermia 1×/week (September 2014).
3. Results
3.1. Treatment Outcome
Both patients of Group A (adjuvant HT/re-RT after primary surgery of RAASB) did
not develop a recurrence during follow-up (FU), with patient No. 1 (Figure 3 A–D) being
observed for 67 months before being lost to FU (LFU), and patient No. 2 for 37 months still
currently under observation today.
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ment fields. The patient died 20 months later. Patient No. 4, who initially had an R1 
Figure 3. Documentation of patient No. 1. (A,B): Re-analysis of former RT 4 12 years prior to RAASB diagnosis. 3D-planning
of adjuvant breast irradiation (July 2007): Tangential irradiation of the breast with 50 Gy and boost to the former tumor bed
with 16 Gy. Due to large diameter boost to the former, tumor bed was applied with parallel opposed photons field up to
16 Gy to minimize the risk of excessive skin fibrosis. (C): Initial RAASB: preoperative situation (August 2011). Note that the
RAASB occurred all ower the breast and was not related to the former boost. (D): Follow up after incomplete resection (R2)
and postoperative re-RT with 5 × 4 Gy + wIRA hyperthermia 1×/week (March 2014). Patient was lost to follow up after
67 months of observation. This exceptional case has been already published as a case report [31].
In Group B (adjuvant HT/re-RT after surgery of recurrent RAASB), patient No. 3
with R1 resection developed a re-recurrence at the border after 6 months which was
directly retreated with the same HT/re-RT schedule, resulting in complete remission (CR)
(Figure 3A–F). Afterwards, the patient received palliative chemotherapy with paclitaxel
due to distant metastasis and developed a new local progression in- and outside the former
treatment fields. The patient died 20 months later. Patient No. 4, who initially had an
R1 resection, developed three consecutive re-recurrences, the first after 3 months. All
re-recurrences were retreated with the same HT/re-RT schedule (5 × 4 Gy, which was
repeated three times in total), each time resulting in CR. This patient is currently (45 months
after surgery of the first recurrence of RAASB) under observation with slow progression.
Documentation is shown in Figure 4A–L. Patient No. 5 with R0 resection is still alive after
10 months, and currently has no evidence of disease (NED).
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Figure 4. Successive photo docu entation of patient o. 4: ( ) 1st S recurrence ( arch 3, 2017), after astecto y
2015. (B) Postoperative situation including skin reconstruction ith esh graft, R1, and contralateral astecto y ( arch
22, 2017) (C) Before start of HT/re-RT, detection of another new recurrence (April 2017, red arrow). (D) End of 1st series,
complete remission (May 2017). (E) New recurrence inside (red arrow, June 2017): 2nd series of HT/re-RT, small field (June
2017). (F) End of 2nd series of HT/re-RT (August 2017): New PD (arrows) outside RT-field (blue circle). Patient cancelled
further treatment due to personal circumstances. (G): Slow, but distinct progression, start of 3rd series (January 2018).
(H) 5 months after 3rd series of HT/re-RT, complete remission (July 2018). (I) New PD inside/border/outside (red arrows).
Start of 4th series (October 2018). (J) Middle of 4th series of HT/re-RT: distinct regression (November 2018). (K) 11 months
after 4th s ries of HT/re-RT (October 2019). (L) FU, due to COVID-19 pandemic, patie t could not present earlier: New PD
o tside field, slowly progres ing (March 2021). Note occurrence of pronou ced telangiectases, mainly limited to regions
subjected to pressure by brassiere and breast prosthesis (additional mechanical factor).
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In Group C (macroscopic recurrence 3–4 weeks after primary radical surgery) patient
No. 6 achieved a CR and has been locally controlled for 16 months, with NED. Patient
No. 7 has just finished the treatment.
In Group D (unresectable RAASB recurrences) patient No. 8 did not respond to
HT/re-RT and died after 1 month. Patient No. 9 achieved a PR with good palliative effect
and survived for 7 months. The clinical situation is presented in Figure 5A,B. Patient
No. 10 is alive with NED for 18 months. In contrast to the other patients of this group, this
patient had a tumor extension limited to the ipsilateral chest wall and was in good general
condition. This led to the decision to retreat her with HT and conventionally fractionated
re-RT.
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Class IV b. Palliative situation. (B) 3 weeks after wIRA-hyperthermia + 5 × 4 Gy (March 2017). PR in
the treatment fields. Relief of pain.
3.2. Toxicity
Acute and chronic toxicity, according to TCAE v5.0, are presented in Table 4. Acute
toxicity occurred in nine out of 10 patients, with patients prese ting with erythema grade
1 (n = 7), and hyperpigmentation grade 1 (n = 6), respectively. No thermal skin damage
was observed by any of the 10 patients. Chronic grade 1 toxicity occurred in two patients:
Patient No. 4 who rec ived four s ries of HT/re-RT (with partially overlapping treatment
fields) showed hy erpigmentation and extensive new telang ectasia (Figure 4L), and
patient No. 10 who developed distinct hyperpigmentation.
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Erythema G1 G1 G1 - G1 G1 G1 - - G1
Hyper-
pigmentation - G1 G1 - G1 G1 - G1 G1 -
Chronic side
effects
Induration - - - - - - - - - -
Hyper-
pigmentation - - - G1 - - - - - G1
New
telangiectases - - - G1 * - - - - - -
Acute and chronic side effects are indicated according to CTCAE grading. * = new telangiectases after 4 series of re-RT/HT with 5 × 4 Gy
1×/week, mainly in mechanically charged skin parts. No thermal related skin damage, e.g., blisters, has been noted. Grade 1 (G1) toxicity
was handled with usual topical skin treatment.
4. Discussion
Given the low incidence of RAASB, there is no standard of care, especially regarding
adjuvant therapies. For the outcome of initial RAASB treatment, quality and extent of
surgery seem to be decisive. Management of the disease in specialized centers may
significantly improve outcome [32]. Larger surgical margins are associated with improved
survival [5,11,33]. Radical surgery, including resection of all pre-irradiated skin areas,
followed by flap reconstructions can significantly decrease the risk of LR, and can lead
to exceptionally high OS rates [2,10,11]. However, radical surgery is associated with a
signi-ficant increase in postoperative complication rates compared to a more conservative
skin resection [11]. In individual cases, the mutilation due to the resection of large skin
areas followed by flap reconstruction, must be weighed against limited medical operability
of older patients as well as the individual demand of the patient [34]. Pre-clinical and
first clinical data on the use of targeted therapies and immunotherapy in the treatment of
angiosarcoma have extensively been discussed by Cao et al. [35].
Data on the efficacy of adjuvant and neoadjuvant chemotherapy (CT) as well as adju-
vant RT in the treatment of first RAASB manifestation are inconsistent [5,36]. Some authors
deny the need for adjuvant RT by presenting good local control rates after radical surgery
alone [5,10,11], whereas other authors emphasize the high risk of local recurrence [14,20].
The risk of RAASB recurrence might be caused by wide-spread and occult microscopic
metastases within the skin, extending from the macroscopic tumor.
There is a comprehensible reluctance of applying RT to a tumor with radiation-induced
etiology. In one multivariate analysis of a populations-based study, adjuvant RT seemed
to be associated with worse OS [13]. In contrast, no impact on OS, but significantly better
RFS, was found in systematic literature reviews [7,9]. Several authors state that their data
do not allow for any recommendation pro or contra adjuvant RT (e.g., [6]).
Smith et al. [20] applied hyperfractionated, accelerated radiotherapy (HART) with
atypically generous radiation field margins of 5–10 cm, pre- or postoperatively. They
reported a median OS of 7 years, and a 5-year OS of 79%. Notably, surgery was included
whenever feasible, with the resection of all pre-irradiated tissues [20]. Efficacy of this
method was confirmed by observations of Donovan et al. [37].
The two patients in our cohort who received adjuvant re-RT/HT after mastectomy of
initial RAASB (group A) did not undergo radical surgery including all pre-irradiated skin.
Nevertheless, they showed local control (LC) for 37 and 67 months respectively, despite the
fact that the latter patient had an R2 resection. In contrast to the review by Dogan et al. [8],
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this patient can be presented as a long-term survivor despite incomplete tumor resection.
Thus, based on this limited and only single institutional experience, we would recommend
adjuvant re-RT/HT, at least for cases where radical surgery is not possible or is refused.
Regarding local recurrences of RAASB as well as unresectable RAASB, limited data
on treatment options and prognoses are available.
Standard treatment of locally recurrent RAASB is again surgical intervention with
curative intent, whenever feasible. However, the rate of re-recurrences is high [5,15], often
developing within a short period of time. Li et al. [11] report a median interval from first to
second local recurrence of just 4 months. In contrast to the first RAASB resection, radical
salvage surgery of recurrences did not significantly increase disease-specific survival [11].
In both first manifestations and recurrences of RAASB, prognosis is poor if R0 resection
cannot be achieved [14]. Consequently, the same applies for unresectable RAASB. In
a systematic review, long-term survivors were only found in cases of complete tumor
resection [8].
De Jong et al. [21] and Linthorst et al. [22] reported their results of combined HT/re-RT
for RAASB. Similar to our analysis, in both retrospective studies the percentage of patients
with recurrent or unresectable disease was far above average compared to other single-
institution reviews. The AMC protocol followed in Amsterdam consisted of a total dose
of 32 Gy (8 × 4 Gy, 2×/week) combined with HT using a 434 MHz microwave technique
given once per week within 1 h after RT [21]. Among 16 patients in AMC Amsterdam,
2 were unresectable, 12 were locally recurrent, and only 2 received combined adjuvant
HT/re-RT after first resection. Complete response rate of macroscopic disease was 58%.
Four of thirteen (31%) patients who were treated for macroscopic disease had good local
control until either death or last follow-up (at 5, 7, 11, and 39 months) [21].
Of 23 patients at Erasmus MC Rotterdam, total RT doses ranged between 32 to 54 Gy
(mean: 35 Gy) followed by HT either once a week for a total of four sessions or twice a
week for a total of six sessions. HT was performed using 434 MHz microwave technique.
Twelve patients presented with unresectable macroscopic disease. Complete response rate
was 56%, and the 3-month, 1- and 3-year LC rates were 54%, 32%, and 22%, respectively.
Eleven patients received adjuvant HT/re-RT after surgery, four with R0, six with R1, and
one with R2 resection. Three-year LC rate was 46%. Late grade 4 RT toxicity was seen in
two patients. One developed osteoradionecrosis of the chest wall requiring resection of
the necrotic area, and the other required debridement for a chronic wound [22]. Molitoris
et al. [38] published a case report on the treatment of a locally recurrent RAASB using a
novel treatment intensification strategy including neoadjuvant HART with concurrent HT,
followed by total mastectomy and flap reconstruction.
Our data are in complete agreement with the aforementioned data on beneficial effects
of combined HT/re-RT in the treatment of recurrent and unresectable RAASB. Among
three patients treated with adjuvant HT/re-RT after resection of recurrent RAASB (group
B), one patient remained locally controlled during lifetime (R0 resection), and the other
two patients who had an R1 resection, experienced a local recurrence. One of these two
patients developed several re-recurrences, which could always be re-treated with the same
schedule, leading to transient complete responses. The first local recurrence was in-field,
and the others grew around the borders or out-of-field despite initial adequate RT- and
HT-volumes (with margins of >5 cm up to 10 cm of all visible lesions). In contrast to
our data on adjuvant re-RT/HT after surgery of first RAASB, re-recurrences following
HT/re-RT after surgery of recurrent RAASB arise the question of higher adjuvant re-RT
doses. However, intensification of re-RT dose is likely to be limited in such situations due
to the presence of critical skin conditions. For example, patients No. 3 and 4 had skin
transplantation applied on an already irradiated tissue (mesh graft, see Figures 3E and 4B),
therefore were at risk for critical toxicities of pre-irradiated or grafted tissue. Notably, none
of the patients died from local progression. Even if no long-lasting LC was achieved, we
have shown that this schedule can be used repeatedly, and is able to induce short-lasting
CR, making this schedule a good palliative treatment option.
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In cases of immediate macroscopic recurrence after surgery and refusal of another
resection (group C), combined HT/re-RT can be utilized. The aforementioned data from
the Netherlands, and the positive experience with patient No. 6 supports this.
The same applies for the palliative treatment of unresectable RAASB (group D).
One heavily pretreated patient with extremely limited life expectancy did not respond
to the treatment, however another patient with a large-sized RAASB achieved partial
remission (PR) and good palliative effect. A patient with general good, condition despite an
unresectable tumor, achieved a CR with local control (FU time 18 months). It is noteworthy
that due to her excellent performance status, a standard fractionation with a semi-curative
total dose was chosen.
The low acute and chronic toxicity rates upon a total re-RT dose of 20 Gy in five
fractions (once weekly) may alleviate concerns of unacceptable toxicity of re-RT of RAASB.
In fact, toxicity was low enough that even with repeat HT/re-RT with a time interval of
only a few months, treatment could safely be delivered. In addition, the patient-friendly
course of five weekly treatment sessions ensures a high compliance.
Note: Benign skin alterations, listed in detail in Table 2, also merit comment. In
particular, the role of vascular degenerative changes, e.g., telangiectases (TA) and ruby
points (cherry hemangioma) remain unclear in the development of RAASB. The incidence
of TA has often been associated with RT-techniques, especially with the use of electrons
≥15 MeV. However, there are also dose-independent genetic risk factors as evidenced by
the association of the XRCC1 (R399Q) DNA repair gene polymorphism with increased risk
of telangiectases irrespective of the patient having received a boost [39]. Interestingly, our
patients presented with TA outside of the former boost field in the remaining, previously
irradiated skin post-mastectomy. This could support the hypothesis of additional gene
factors. This observation is in agreement with Fodor et al. [40], who described post-RT
related grade 2 TA in two out of eight patients. Brenn and Fletcher [41,42] associated
TA with other post-radiation atypical vascular lesions (AVL) as a possible morphologic
continuum in the development of cutaneous angiosarcoma. However, a clear correlation
is missing, due to the small number of described cases. Ashack et al. [43] did not find
any correlation of late RT-sequelae of skin and RAASB. Fair hair and skin color had been
associated with the incidence of radiation induced basal cell carcinoma [44] but to our
knowledge, it has never been as an important factor with regard to RAASB. Despite the
occurrence of RAASB in our patients with fair hair, skin type I or II, the understanding of
possible correlations is poor, due to the low number of patients. Banks et al. [45] reported
skin fibrosis after previous RT in 19/56 patients. In our study 5 out of 10 patients presented
with ruby points (cherry hemangiomas), and 2 with fibrosis of the remaining skin after
mastectomy of RAASB. Another two patients had severe postoperative complications
after breast conservation before the onset of RT (Table 1), but the fibrotic tissue was
removed during the mastectomy. Based on these rare observations it is too early to give
any recommendations to radiation oncologists for how to take care of AVLs at the onset of
first RT of breast cancer. Nevertheless, we suggest noting cherry hemangiomas and other
clinical observations in future prospective studies.
5. Conclusions and Outlook
Given the poor prognosis and limited treatment options in cases of recurrent or
unresectable RAASB, our data and reports from the Netherlands suggest combined HT/re-
RT as a beneficial palliative treatment option. In addition, combined HT/re-RT should
be considered as an adjuvant treatment of RAASB when radical surgery, including all
pre-irradiated skin areas, is not feasible. Low toxicity rates using thermography-controlled,
contactless wIRA-hyperthermia immediately followed by hypofractionated re-RT (5 × 4 Gy
treatments delivered once a week) allows for repeat re-irradiations in case of re-recurrences.
The applied wIRA-hyperthermia method seems to be a good technical solution for heating
RAASB patients, because it produces very large treatment fields. In addition, most of these
tumors occur within the first 5 mm from the surface and can thus be heated adequately.
Cancers 2021, 13, 3911 15 of 17
Prospective data on the use of combined HT/re-RT and corresponding multi-center
studies are required.
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RAASB = radiation associated angiosarcoma of the breast
LRBC = locally recurrent breast cancer
RT = radiotherapy
re-RT = re-irradiation
HART = hypofractionated accelerated radiotherapy
wIRA = water filtered infrared-A
HT = hyperthermia
CT = chemotherapy
H = hormone therapy
S = surgery
OS = overall survival
LR = local recurrence
LRR = local recurrence rate
RFS = recurrence-free survival
FU = follow up
LFU = lost to follow-up
CR = complete remission
PR = partial remission
SD = stable disease
PD = progressive disease
LC = local control
NED = no evidence of disease
TA = telangiectases
AVL = atypical vascular lesions
Dx = diagnosis
TM = total mastectomy
Cobalt-60 = radiation unit using 60Co sources
References
1. Laé, M.; Lebel, A.; Hamel-Viard, F.; Asselain, B.; Trassard, M.; Sastre, X.; Kirova, Y.M. Can c-myc amplification reliably dis-
criminate postradiation from primary angiosarcoma of the breast? Cancer Radiother. 2015, 19, 168–174. [CrossRef]
2. Mito, J.K.; Mitra, D.; Barysauskas, C.M.; Marino-Enriquez, A.; Morgan, E.A.; Fletcher, C.D.M.; Raut, C.P.; Baldini, E.H.; Doyle,
L.A. A comparison of outcomes and prognostic features for radiation-associated angiosarcoma of the breast and other radia-tion-
associated sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2019, 104, 425–435. [CrossRef] [PubMed]
Cancers 2021, 13, 3911 16 of 17
3. Bonito, F.J.P.; de Almeida Cerejeira, D.; Dahlstedt-Ferreira, C.; Coelho, H.O.; Rosas, R. Radiation-induced angiosarcoma of the
breast: A review. Breast J. 2019, 26, 458–463. [CrossRef] [PubMed]
4. Rombouts, A.J.M.; Huising, J.; Hugen, N.; Siesling, S.; Poortmans, P.M.; Nagtegaal, I.D.; de Wilt, J.H.W. Assessment of
radiotherapy-associated angiosarcoma after breast cancer treatment in a Dutch population-based study. JAMA Oncol. 2019, 5,
267–269. [CrossRef] [PubMed]
5. Salminen, S.H.; Wiklund, T.; Sampo, M.M.; Tarkkanen, M.; Pulliainen, L.; Böhling, T.O.; Tukiainen, E.; Hukkinen, K.;
Blomqvist, C.P. Treatment and prognosis of radiation-associated breast angiosarcoma in a nationwide population. Ann. Surg.
Oncol. 2019, 27, 1002–1010. [CrossRef]
6. Taffurelli, M.; Pellegrini, A.; Meattini, I.; Orzalesi, L.; Tinterri, C.; Roncella, M.; Terribile, D.; Caruso, F.; Tazzioli, G.; Pollini, G.; et al.
Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC).
Breast 2019, 45, 56–60. [CrossRef] [PubMed]
7. Depla, A.L.; Scharloo-Karels, C.H.; de Jong, M.A.A.; Oldenborg, S.; Kolff, M.W.; Oei, S.B.; van Coevorden, F.; van Rhoon, G.C.;
Baartman, E.A.; Scholten, R.J.; et al. Treatment and prognostic factors of radiation-associated angio-sarcoma (RAASB) after
primary breast cancer: A systematic review. Eur. J. Cancer 2014, 50, 1779–1788. [CrossRef]
8. Dogan, A.; Kern, P.; Schultheis, B.; Häusler, G.; Rezniczek, G.A.; Tempfer, C.B. Radiogenic angiosarcoma of the breast: Case report
and systematic review of the literature. BMC Cancer 2018, 18, 463. [CrossRef] [PubMed]
9. Abdou, Y.; Elkhanany, A.; Attwood, K.; Ji, W.; Takabe, K.; Opyrchal, M. Primary and secondary breast angiosarcoma: Single
center report and a meta-analysis. Breast Cancer Res. Treat. 2019, 178, 523–533. [CrossRef] [PubMed]
10. Gutkin, P.M.; Ganjoo, K.N.; Lohman, M.; von Eyben, R.; Charville, G.W.; Nazerali, R.S.; Dirbas, F.M.; Horst, K.C. Angiosar-coma
of the breast: Management and outcomes. Am. J. Clin. Oncol. 2020, 43, 820–825. [CrossRef] [PubMed]
11. Li, G.Z.; Fairweather, M.; Wang, J.; Orgill, D.P.; Bertagnolli, M.M.; Raut, C.P. Cutaneous radiation-associated breast angio-sarcoma:
Radicality of surgery impacts survival. Ann. Surg. 2017, 265, 814–820. [CrossRef]
12. Salminen, S.; Sampo, M.M.; Böhling, T.O.; Tuomikoski, L.; Tarkkanen, M.; Blomqvist, C. Radiation-associated sarcoma after breast
cancer in a nationwide population: Increasing risk of angiosarcoma. Cancer Med. 2018, 7, 4825–4835. [CrossRef]
13. Yin, M.; Wang, W.; Drabick, J.J.; Harold, H.A. Prognosis and treatment of non-metastatic primary and secondary breast an-
giosarcoma: A comparative study. BMC Cancer 2017, 17, 295. [CrossRef] [PubMed]
14. Seinen, J.M.; Styring, E.; Verstappen, V.; von Steyern, F.V.; Rydholm, A.; Suurmeijer, A.J.H.; Hoekstra, H.J. Radiation-associated
angiosarcoma after breast cancer: High recurrence rate and poor survival despite surgical treatment with R0 resection. Ann. Surg.
Oncol. 2012, 19, 2700–2706. [CrossRef]
15. Amajoud, Z.; Vertongen, A.S.; Weytens, R.; Hauspy, J. Radiation induced angiosarcoma of the breast: Case series and review of
the literature. Facts Views Vis. Obgyn. 2018, 10, 215–220.
16. Alves, I.; Marques, J.C. Radiation-induced angiosarcoma of the breast: A retrospective analysis of 15 years’ experience at an
oncology center. Radiol. Bras. 2018, 51, 281–286. [CrossRef] [PubMed]
17. Torres, K.E.; Ravi, V.; Kin, K.; Yi, M.; Guadagnolo, B.A.; May, C.D.; Arun, B.K.; Hunt, K.K.; Lam, R.; Lahat, G.; et al. Long-term
outcomes in patients with radiation-associated angio-sarcomas of the breast following surgery and radiotherapy for breast cancer.
Ann. Surg. Oncol. 2013, 20, 1267–1274. [CrossRef]
18. Nestle-Krämling, C.; Bölke, E.; Budach, W.; Peiper, M.; Niederacher, D.; Janni, W.; Eisenberger, C.F.; Knoefel, W.T.; Scherer, A.;
Baldus, S.E.; et al. Hämangiosarkom nach brusterhaltender Therapie beim Mammakarzinom: Vier Fallbeispiele mit moleku-
largenetischer Diagnostik und Literaturübersicht [Hemangiosarcoma after breast-conserving therapy of breast cancer: Report of
four cases with molecular genetic diagnosis and literature review]. Strahlenther. Onkol. 2011, 187, 656–664. (In German) [CrossRef]
19. Cugh, R.; Sabel, M.S.; Feng, M.; Maki, R.; Hayes, D.F.; Chagpar, A.; DeLaney, T.F. Breast Sarcoma: Treatment. Available online:
https://www.uptodate.com/contents/breast-sarcoma-treatment/print (accessed on 1 May 2021).
20. Smith, T.L.; Morris, C.G.; Mendenhall, N.P. Angiosarcoma after breast-conserving therapy: Long-term disease control and late
effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol. 2013, 53, 235–241. [CrossRef] [PubMed]
21. De Jong, M.; Oldenborg, S.; Oei, S.; Griesdoorn, V.; Kolff, M.; Koning, C.; van Tienhoven, G. Reirradiation and hyperthermia for
radiation-associated sarcoma. Cancer 2011, 47, S667–S668. [CrossRef]
22. Linthorst, M.; van Geel, A.; Baartman, E.; Oei, S.; Ghidey, W.; van Rhoon, G.; van Der Zee, J. Effect of a combined surgery,
re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall. Strahlenther. Onkol.
2013, 189, 387–393. [CrossRef]
23. Thews, O.; Li, Y.; Kelleher, D.K.; Chance, B.; Vaupel, P. Microcirculatory functions, tissue oxygenation, microregional redox
status and ATP distribution in tumors upon localized infrared-A-hyperthermia at 42 ◦C. Adv. Exp. Med. Biol. 2003, 530, 237–247.
[CrossRef]
24. Thomsen, A.R.; Saalmann, M.R.; Kollefrath, M.; Grosu, A.L.; Nicolay, N.H.; Scholber, J.; Notter, M.; Vaupel, P. Oxygenation status
in human skin, subcutis and superficial tumor lesions upon thermography-controlled wIRA-hyperthermia: Implications for
thermoradiation of superficial tumors. Strahlenther. Onkol. 2021, 197 (Suppl. 1). [CrossRef]
25. Zhang, J.; Zhao, B.; Chen, S.; Wang, Y. Near-infrared light irradiation induced mild hyperthermia enhances glutathione de-pletion
and DNA interstrand cross-link formation for efficient chemotherapy. ACS Nano 2020, 14, 14831–14845. [CrossRef]
26. Oei, A.; Kok, H.; Oei, S.; Horsman, M.; Stalpers, L.; Franken, N.; Crezee, J. Molecular and biological rationale of hyperthermia as
radio- and chemosensitizer. Adv. Drug Deliv. Rev. 2020, 163, 84–97. [CrossRef] [PubMed]
Cancers 2021, 13, 3911 17 of 17
27. Lee, C.T.; Mace, T.; Repasky, E.A. Hypoxia-driven immunosuppression: A new reason to use thermal therapy in the treatment of
cancer? Int. J. Hyperth. 2010, 26, 232–246. [CrossRef]
28. Notter, M.; Piazena, H.; Vaupel, P. Hypofractionated re-irradiation of large-sized recurrent breast cancer with thermography-
controlled, contact-free water-filtered infrared-A hyperthermia: A retrospective study of 73 patients. Int. J. Hyperth. 2017, 33,
227–236. [CrossRef] [PubMed]
29. Notter, M.; Thomsen, A.R.; Nitsche, M.; Hermann, R.M.; Wolff, H.; Habl, G.; Münch, K.; Grosu, A.L.; Vaupel, P. Combined wIRA-
hyperthermia and hypofractionated re-irradiation in the treatment of locally recurrent breast cancer: Evaluation of thera-peutic
outcome based on a novel size classification. Cancers 2020, 12, 606. [CrossRef]
30. Vaupel, P.; Piazena, H.; Müller, W.; Notter, M. Biophysical and photobiological basics of water-filtered infrared-A hyperthermia of
superficial tumors. Int. J. Hyperth. 2018, 35, 26–36. [CrossRef]
31. Stutz, E.; Puric, E.; Datta, N.; Bodis, S.; Notter, M. Strahlenassoziiertes Angiosarkom der Brust: Was können wir aus Fallberichten
lernen? Info Onkol. Hämatol. 2017, 5, 4. (In German)
32. Feinberg, L.; Srinivasan, A.; Singh, J.K.; Parry, M.; Stevenson, J.; Jeys, L.; Grimer, R.; Peart, F.; Warner, R.; Ford, S.; et al. Impact
of specialist management on survival from radiation-associated angiosarcoma of the breast. Br. J. Surg. 2018, 105, 401–409.
[CrossRef]
33. Lehnhardt, M.; Bohm, J.; Hirsch, T.; Behr, B.; Daigeler, A.; Harati, K. Strahlen-induzierte Angiosarkome der Brust [Radiation-
induced angiosarcoma of the breast]. Handchir. Mikrochir. Plast. Chir. 2017, 49, 103–110. (In German) [CrossRef]
34. Wiebringhaus, P.; Gröger, A.; Menke, H. Das sekundäre Angiosarkom der Brust nach brusterhaltender Therapie [Secondary
angiosarcoma of the breast after breast-conserving therapy]. Handchir. Mikrochir. Plast. Chir. 2015, 47, 134–138. (In German)
[CrossRef] [PubMed]
35. Cao, J.; Wang, J.; He, C.; Fang, M. Angiosarcoma: A review of diagnosis and current treatment. Am. J. Cancer Res. 2019, 9,
2303–2313. [PubMed]
36. Hasan, S.; Metzger, A.; Wegner, R.; Verma, V.; Hilton, C.; Julian, T.; Trombetta, M. Management trends and outcomes of breast
angiosarcoma: Is breast conservation feasible? Breast J. 2019, 25, 1230–1234. [CrossRef]
37. Donovan, E.K.; Corbett, T.; Vansantvoort, J.; Kak, I.; Popvic, S.; Heller, B. Radical chest wall resection and hyperfractionated
accelerated radiotherapy for radiation-associated angiosarcoma of the breast: A safe and effective treatment strategy. Breast J.
2017, 24, 245–252. [CrossRef] [PubMed]
38. Molitoris, J.K.; Chhabra, A.; Snider, J.W.; Harvilla, N.; Okonkwo, N.; Nichols, E.M.; Vujaskovic, Z.; Ioffe, O.B.; Kesmodel, S.B.;
Feigenberg, S.J. Intensification of treatment for angiosarcoma of the breast with accelerated hyperfractionated radiation, hyper-
thermia, and surgical resection. Cureus 2017, 9, e1406. [CrossRef]
39. Giotopoulos, G.; Symonds, R.P.; Foweraker, K.; Griffin, M.; Peat, I.; Osman, A.; Plumb, M. The late radiotherapy normal tissue
injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br. J.
Cancer 2007, 96, 1001–1007. [CrossRef]
40. Fodor, J.; Orosz, Z.; Szabó, E.; Sulyok, Z.; Polgár, C.; Zaka, Z.; Major, T. Angiosarcoma after conservation treatment for breast
carcinoma: Our experience and a review of the literature. J. Am. Acad. Dermatol. 2006, 54, 499–504. [CrossRef]
41. Brenn, T.; Fletcher, C.D.M. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: Clinicopathologic
ana-lysis of 42 cases. Am. J. Surg. Pathol. 2005, 29, 983–996. [CrossRef]
42. Brenn, T.; Fletcher, C.D.M. Postradiation vascular proliferations: An increasing problem. Histopathology 2006, 48, 106–114.
[CrossRef] [PubMed]
43. Ashack, K.A.; Kuritza, V.; Visconti, M.J.; Ashack, L. Dermatologic sequelae associated with radiation therapy. Am. J. Clin.
Dermatol. 2020, 21, 541–555. [CrossRef] [PubMed]
44. Watt, T.C.; Inskip, P.D.; Stratton, K.; Smith, S.A.; Kry, S.; Sigurdson, A.J.; Stovall, M.; Leisenring, W.; Robison, L.L.; Mertens, A.C.
Radiation-related risk of basal cell carcinoma: A report from the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 2012, 104,
1240–1250. [CrossRef] [PubMed]
45. Banks, J.; George, J.; Potter, S.; Gardiner, M.D.; Ives, C.; Shaaban, A.M.; Singh, J.; Sherriff, J.; Hallissey, M.T.; Horgan, K.; et al.
Breast Angiosarcoma Surveillance Study: UK national audit of management and outcomes of angiosarcoma of the breast and
chest wall. Br. J. Surg. 2021, 108, 388–394. [CrossRef]
